Paper Details

  1. Home
  2. Paper Details

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Author: , Andrade-VillanuevaJaime, ArribasJose R, BrarIndira, BrunettaJason, CavassiniMatthias, ChengAndrew K, DeJesusEdwin, DiPerriGiovanni, ElionRichard, GirardPierre-Marie, HuhnGregory, KoenigEllen, LiuYa-Pei, MadrugaJose Valdez, McCallisterScott, MillsAnthony, OrkinChloe, PlummerAndrew, ShamblawDavid, StephensJeffrey L, Van LunzenJan, WohlDavid A

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the efficacy, safety, and tolerability of switching to a regimen containing tenofovir alafenamide versus remaining on tenofovir disoproxil fumarate. Tenofovir alafenamide reduces tenofovir plasma concentrations by 90%, potentially decreasing off-target side effects. The study aimed to determine if switching to tenofovir alafenamide would maintain efficacy while improving safety and tolerability.
Paper Details　
Original Abstract of the Article :
Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with renal toxicity and reduced bone mineral density. Tenofovir alafenamide is a novel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasing off-target side-effects. We aimed to ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1473-3099(15)00348-5

データ提供：米国国立医学図書館（NLM）

The Shifting Sands of HIV Treatment: A New Prodrug for a Smoother Journey

This study explores the effectiveness of tenofovir alafenamide, a new prodrug for HIV treatment, compared to tenofovir disoproxil fumarate. It’s like a camel caravan navigating the desert of HIV treatment, seeking new and improved routes to health. The authors conducted a randomized, controlled trial to assess the efficacy, safety, and tolerability of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults with HIV. They found that tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate in terms of efficacy and tolerability. It’s like discovering a smoother path through the desert, offering a more comfortable and sustainable journey.

The Promise of Tenofovir Alafenamide for HIV Treatment

This study highlights the potential of tenofovir alafenamide as a safe and effective alternative to tenofovir disoproxil fumarate in HIV treatment. It’s like finding a new oasis in the desert, offering a haven of health and well-being for individuals with HIV. The findings suggest that tenofovir alafenamide can provide similar efficacy with a better safety profile, reducing the risk of renal toxicity and bone mineral density loss.

The Journey Towards a Cure: A Desert of Hope

This study reminds us that the journey towards a cure for HIV is ongoing, like a camel caravan traversing a vast desert, seeking a path to a healthier future. The development of new drugs like tenofovir alafenamide represents a significant step forward in the fight against HIV. It’s like finding a new source of water in the desert, offering a promise of hope and a better future for those living with HIV.

Dr. Camel's Conclusion

This study reminds us that the desert of HIV treatment is constantly evolving. It's like a challenging journey, but with ongoing research and innovation, we can find new ways to improve the lives of people living with HIV. Tenofovir alafenamide represents a promising new path, offering a smoother and more sustainable journey towards health and well-being.

Date :
  1. Date Completed 2016-06-13
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

26538525

DOI: Digital Object Identifier

10.1016/S1473-3099(15)00348-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.